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============

Providing relief from pain and anxiety associated with diagnostic and therapeutic procedures has become an ethical imperative in children as well as a measured quality indicator from the family's perspective. This, along with a tremendous increase in the number of procedures performed on children outside the operating room, has led to non-anesthesiologists, particularly emergency physicians, taking a key role in the administration of procedural sedation and analgesia (PSA) to children. It has been estimated that roughly a quarter million children will receive PSA in the emergency departments (EDs) annually and that children under 2 years of age constitute roughly 20--30% of those \[[@CR1], [@CR2]\]. It has been shown that pain in infants and toddlers is poorly recognized and documented \[[@CR3], [@CR4]\], predisposing them to receive less analgesia when compared with older children \[[@CR5]\]. Commonly used medications for PSA such as ketamine are relatively contraindicated in very young children (\<6 months of age) because of an association with increased risk of airway complications \[[@CR6]\]. Inadequate sedation and analgesia predisposes to procedural failure, parental anxiety and dissatisfaction, and poor quality of care. The anatomic differences in the airway like smaller airway diameter, longer and floppy epiglottis, and the physiologic differences in drug metabolism between younger and older children could predispose younger children to a higher risk for adverse events related to sedation. Studies have shown contrasting results regarding association of age and adverse events related to PSA. While some studies have found children less than 2 years of age to be at an increased risk for adverse events related to PSA \[[@CR7], [@CR8]\], other studies have found no association between age and adverse events related to PSA \[[@CR9], [@CR10]\]. To our knowledge, there have been no studies that have focused exclusively on PSA in children less than 2 years of age. The main objective of our study is to describe PSA in children less than 2 years of age in the ED of a tertiary care children's hospital. Additionally, we will describe the indications for PSA, medications used, efficacy of sedation, and adverse events related to sedation in this group of children.

Methods {#Sec2}
=======

We conducted a retrospective chart review of medical records, including sedation records of all children less than 2 years of age who underwent PSA in our ED over a period of 2.5 years from January 2005 to June 2007. Our ED is a level 1 trauma center of a tertiary care, freestanding children's hospital with greater than 90,000 visits a year. Study subjects were identified using their date of birth and the Current Procedural Terminology (CPT) code used for procedural sedation in the ED (99141). All patients who undergo PSA in the ED have a standardized nursing sheet that records all events during the PSA procedure till discharge from the ED. Children who received only pain medication, or analgesia, and those who underwent sedation in the imaging department by the sedation team were excluded from the study.

We used a standardized data abstraction sheet to collect patient demographic variables, past medical history including American Society of Anesthesiologists (ASA) class, indications and medications used for PSA, and service of the physician (for example ED attending or consultant services like pediatric surgery, hand surgery, etc.) performing the procedure. We collected data on effectiveness of sedation, adverse events related to sedation, the interventions performed to overcome the adverse events, and ED disposition. For the purposes of the study, the following were considered as adverse events: oxygen desaturations less than 93% for greater than 15 s, apnea, aspiration, laryngospasm, bradycardia, hypotension, paradoxical reaction, emesis, and any other that were reported by the sedating physician as an adverse event. Sedation was deemed as inadequate if the procedure was completed but with significant patient distress as documented in the nursing notes or movement during the procedure. Failed sedation was defined as the inability to complete the procedure in the ED. All data were abstracted and entered by the principal investigator to maintain consistency. All data were double entered for accuracy. This study was approved by the Institutional Review Board.

Statistical analysis was conducted using the commercial software SAS v. 9.1 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics (frequency, mean, standard deviation, and 95% confidence interval) was used to summarize the characteristics of the study sample. The chi-square test and Student's *t*-test were used to compare the differences in the number of medications used and medication dosages between patients with adequate sedation versus those with inadequate sedation.

Results {#Sec3}
=======

Over the study period of 2.5 years, there were a total of 225,750 patient visits to the ED. A total of 1,235 PSAs were performed, of which 14.6% (180/1235) were performed in children under the age of 2 years. Of these, seven children were excluded from review and analysis. We were unable to obtain medical records for 5 children, 1 child received only analgesia, and 1 child was sedated by the sedation service for diagnostic imaging, leaving 173 patients eligible for analysis. The majority of patients (73%, 126/173) receiving PSA were between 1 and 2 years of age (Fig. [1](#Fig1){ref-type="fig"}), 54.3% (94/173) were male, and 96.5% (167/173) belonged to ASA class 1. Incision and drainage (45.0%, 78/173) and laceration repair (32.4%, 56/173) were the two most common indications for PSA in this age group (Fig. [2](#Fig2){ref-type="fig"}). The procedure was performed by the consultant services (non-ED attending) in 77% (133/173) of the patients. The average duration of the procedure requiring PSA was 17.3 ± 13.9 minu The majority of the children received a combination of two medications for PSA (80.4%, 139/173). Ketamine/midazolam (62.4%, 108/173) was the most common combination medication used for PSA followed by morphine/midazolam (16.1%, 28/173) reflective of institutional practice. Fig. 1Age distribution of study populationFig. 2Indications for PSA

Sedation was "inadequate" in 5.8% (10/173) of the patients. There was no difference in patient age, number of medications used, and mean weight-based dosage of ketamine and morphine used between those with adequate versus inadequate sedation. The mean dosage of midazolam used was slightly higher in those children with inadequate sedation (Table [1](#Tab1){ref-type="table"}). The planned procedure could not be completed successfully in only two children. Both of these were procedure failures and not sedation failures. The first case was a 2-month-old male child who was adequately sedated with ketamine and midazolam but failed reduction of an incarcerated inguinal hernia. This child also subsequently developed apnea related to PSA. The second patient was a 6-month-old female child who had to be taken to the operating room after failure of reduction of hernia under sedation with morphine (0.2 mg/kg) and midazolam (0.1 mg/kg). Table 1Comparison of children with adequate versus inadequate sedationVariableAdequate sedationInadequate sedation*p* value*n*Percentage*n*PercentageAge 0--1 years4393.536.50.820 1--2 years11894.475.6No. of medication(s) received One2213.8220.00.582 Two or more13886.2880.0Medication dosage*n*mg/kg (SD)*n*mg/kg (SD) Morphine290.140 (0.078)20.120 (0.071)0.731 Versed1330.099 (0.057)80.144 (0.045)0.032 Ketamine1281.211 (0.568)81.326 (0.348)0.571

Of the patients, 5.8% (10/173) experienced adverse events related to PSA (Table [2](#Tab2){ref-type="table"}). Most (9/10) of these adverse events were minor in nature and included transient oxygen desaturations (1.7%, 3/174), emesis (2.3%, 4/173), and others(1.2%, 2/173), which included snoring and development of transient stridor. All these adverse events resolved with minimal interventions including repositioning the airway, oral suctioning, and oxygen supplementation. Table 2Adverse events related to procedural sedation and analgesiaAge (months)SexProcedureMedication dose (mg/kg)Adverse eventTreatment2MHernia reductionMidazolam (2)Apnea, bradycardiaIntubationKetamine (0.2)15MLaceration repairMidazolam (0.17)Oxygen desaturationOxygen supplementationKetamine (1.29)10MIncision & drainageMidazolam (0.09)Oxygen desaturationOxygen supplementationKetamine (0.95)22MLaceration repairMidazolam (0.13)Oxygen desaturationOxygen supplementationKetamine (1.52)15FLaceration repairMidazolam (0.13)StridorAirway repositioning, racemic epinephrineKetamine (1.02)9MIncision & drainageKetamine (0.98)SnoringAirway repositioning22MLaceration repairMidazolam (0.13)VomitingSuctionKetamine (1.52)4MIncision & drainageMidazolam (0.14)VomitingSuctionMorphine (0.21)23MLaceration repairMidazolam (0.09)VomitingSuctionKetamine (0.89)23FLaceration repairMidazolam (0.09)VomitingSuctionKetamine (0.94)

One study subject experienced a serious adverse event, in the form of apnea and bradycardia, which required intubation. This was a 2-month-old male child with a history of recent upper respiratory tract infection and an overnight admission for bronchiolitis 1 week prior to the visit that required PSA. He required PSA for an incarcerated right-sided inguinal hernia. He received two doses of ketamine (total of 2 mg/kg) and two doses of midazolam (total of 0.2 mg/kg). Approximately 30 min after the failed reduction he developed persistent hypoxia and bradycardia which did not respond to supplemental oxygen or airway maneuvers and subsequently became apneic requiring endotracheal intubation. He was extubated 2 days later and had an uncomplicated recovery.

Discussion {#Sec4}
==========

Our study results suggest that PSA is safe and can be performed successfully in children less than 2 years of age. These results are consistent with previous studies which have demonstrated the proficiency of emergency medicine physicians to deliver PSA effectively in children of all age groups \[[@CR9], [@CR11], [@CR12]\]. There were only two failed sedations in our study. Both our "failed sedations" occurred in the youngest age group (\<6 months of age), were procedure failures, and occurred during hernia reduction. This may underscore the need for reduction in the operating room rather than in the emergency department for the youngest children.

Interestingly, abscess incision and drainage was the most common indication for PSA in our study population. Other studies have reported that fracture reduction and laceration repair are more common indications \[[@CR9], [@CR12]\], and the difference in indications could be reflective of our study population or could reflect the reported increase in the ED visits for skin and soft tissue infections secondary to the emergence of community-acquired methicillin-resistant *Staphylococcus aureus* \[[@CR13]\].

Our study demonstrates a low adverse event rate related to PSA in children less than 2 years of age. More importantly, most of the observed adverse events were minor and transient requiring only minimal intervention. Malviya et al. \[[@CR8]\] in their study of adverse events related to sedation of children by non-anesthesiologists concluded that young age (less than 1 year of age) was a predictor of adverse events. However, the majority of patients in their study underwent sedation for diagnostic imaging and three fourths of the children were sedated with chloral hydrate, a drug that is not commonly used for PSA in the emergency department. Although Peña et al. \[[@CR9]\] in their prospective study of adverse events related to PSA in a pediatric emergency department reported that one third of the observed total adverse events occurred in children up to 2 years of age, in their final analysis they were unable to find a difference between those who experienced adverse events and those who did not, with respect to age.

We did have one serious adverse event related to PSA in our study. This patient serves to highlight that safety of PSA is dependent on patient characteristics and that adequate monitoring is essential during and after the procedure until the patient is ready for discharge. It also emphasizes the need for physicians providing PSA to have necessary skills to rescue the patient from a deeper level of sedation than that intended for the procedure and provide appropriate cardiopulmonary support if needed \[[@CR14]\].

Limitations {#Sec5}
===========

The biggest limitation to our study was its retrospective nature, which could have limited the amount of information that was available. We reviewed not only the medical records of the study children but also the sedation records. The sedation records were audited every 3 months during the study period to ensure completeness of data recorded in these records. There could have also been variation amongst physicians and nurses as to what constitutes an adverse event related to PSA leading to overreporting or underreporting of the adverse event rate. But this under/overreporting is less likely because of a standardized monitoring plan for all patients undergoing PSA in the ED. We also did not study the adverse events after discharge from the emergency department. This study was undertaken at a tertiary care pediatric emergency department and the findings may not be applicable to other settings with different levels of training of the sedation providers and different monitoring practices. Our center also uses ketamine predominantly for PSA. The adverse event rate and profile may be different in other centers which use other medications for PSA.

Conclusion {#Sec6}
==========

Our study shows that PSA can be administered effectively and safely with few adverse events to children less than 2 years of age in a pediatric emergency department.
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